

PERSONAL INFORMATION

Iva Klarica Domjanovic

WORK EXPERIENCE

-
- January 2021- Present **Senior advisor for Non-Clinical and Clinical Assessment**
Agency for Medicinal Products and Medical Devices (HALMED) (Croatia)
assessment of PK studies in centralised procedures and assessment of bioequivalence studies and
biowaivers in national, decentralised and centralised procedures. Involvement in the scientific
advice.
- December 2018-January 2021 **Advisor for Non-Clinical and Clinical Assessment**
Agency for Medicinal Products and Medical Devices (HALMED) (Croatia)
- Assessment of PK studies in centralised procedures. - Assessment of bioequivalence studies and
biowaivers in national, decentralised and centralised procedures.
- October 2016-December 2018 **Senior Associate Specialist for Non-clinical and Clinical documentation**
Agency for Medicinal Products and Medical Devices (HALMED) (Croatia)
- Assessment of bioequivalence studies and biowaivers in national and decentralised procedures.
- October 2014-October 2016 **Senior Associate for Regulatory Affairs**
Agency for Medicinal Products and Medical Devices (HALMED) (Croatia)
- Validation of applications for granting marketing authorization, renewal of marketing authorization
and applications for variations.
- June 2012-October 2014 **Associate for Regulatory Affairs**
Agency for Medicinal Products and Medical Devices (HALMED) (Croatia)
- Validation of applications for granting marketing authorization, renewal of marketing authorization
and applications for variations.
- January 2011-January 2012 **Community pharmacist**
Ljekarne zagrebake upanije (Croatia)
- Dispensing medicines, patient care, interaction checking, reports of adverse drug reactions

EDUCATION AND TRAINING

-
- September 2019- Present **MSc Model-based Drug Development**
The University of Manchester, Faculty of Biology, Medicine and Health, Division of
Pharmacy and Optometry (United Kingdom)
- November 2011-May 2018 **Doctor of Philosophy (Ph.D.)**
University of Zagreb, Faculty of Science, Division of Biology, doctoral programme
(Croatia)
- July 2005-October 2010 **Master of Pharmacy**
University of Zagreb, Faculty of Pharmacy and Biochemistry (Croatia)

ADDITIONAL INFORMATION

-
- Expertise** Pharmacogenomics, pharmacokinetics
- Publications** - Krasniqi V, Dimovski A, Domjanovic IK, Bilic I, Bozina N (2016) How polymorphisms of the
cytochrome P450 genes affect ibuprofen and diclofenac metabolism and toxicity. Arh Hig Rada
Toksikol 67(1): 1-8. - Bozina N, Klarica Domjanovic I, Ganoci L (2017) Farmakogenomika u
pedijatrijskoj populaciji. Paediatr Croat 61 (Supl 1): 184-192. - Lovric M, Cajic I, Petelin Gadze Z,

Klarica Domjanovic I, Bozina N (2018) Effect of antiepileptic drug comedication on lamotrigine concentrations. *Croat Med J* 59(1): 13-19. - Klarica Domjanovic I, Lovric M, Trkulja V, Petelin-Gadze Z, Ganoci L, Cajic I, Bozina N. (2018) Interaction between ABCG2 421C>A polymorphism and valproate in their effects on steady-state disposition of lamotrigine in adults with epilepsy. *Br J Clin Pharmacol.* 84(9):2106-2119. - Bozina N, Sporis IS, Bozina T, Klarica-Domjanovic I, Tvrdeic A, Sporis D (2019) Pharmacogenetics and the treatment of epilepsy: what do we know?. *Pharmacogenomics.* 20(15):1093-1101. doi: 10.2217/pgs-2019-0085 Bozina N, Vrkic Kirhmajer M, Simicevic L, Ganoci L, Mirosevic Skvrce N, Klarica Domjanovic I, Mercep I(2020)Use of pharmacogenomics in elderly patients treated for cardiovascular diseases.*Croat Med J.* Apr 30;61(2):147-158, Bozina N, Ganoci L, Simicevic L, Gvozdanovic K, Domjanovic IK, Fistrek Pric M, Kriz T, Boric Bilusic A, Laganovic M, Bozina T (2021). Drug-drug-gene interactions as mediators of adverse drug reactions to diclofenac and statins: a case report and literature review. *Arh Hig Rada Toksikol.*;72(3):114-128. Published congress abstracts: - Bozina N, Mirosevic Skvrce N, Ganoci L, Mas P, Klarica Domjanovic I, Simic I (2016) Integrating Pharmacovigilance and Pharmacogenomics: Croatian Experience. *Clin Ther* 6;38(10S):e23 - Ganoci L, Lovric M, Zivkovic M, Sagud M, Klarica Domjanovic I, Bozina N (2016) The Role Of Cyp2d6, Cyp3a4/5, And Abcb1 Polymorphisms In Patients Using Long-Acting Injectable Risperidone. *Clin Ther* 6;38(10S): e10-e11

- Domjanovic I.K., Skvrce N.M., Bilusic A.B., Ganoci L., Bozina N., Sertic D (2018) Pharmacogenetic Markers of Adverse Reactions of Tyrosine Kinase Inhibitors - Case Report. Abstracts from First Nordic conference on personalized medicine 2018 in Nyborg, Denmark. *Basic Clin Pharmacol Toxicol*, 123: 3-14. doi:10.1111/bcpt.13020

Projects 2021 EU funded Twinning project "Support to the Agency for Medicines and Medical Devices of Montenegro (CALIMS)" MN 16 IPA HE 01 20. Participated as expert in the field of bioequivalence.

Memberships - Member of Croatian Chamber of Pharmacists- Croatian Society of Pharmacogenomics

Other Relevant Information